

## Original Article

\*Authors contributed equally.

**Cite this article:** Liu Y *et al* (2024). Temporal changes in brain morphology related to inflammation and schizophrenia: an omnigenic Mendelian randomization study. *Psychological Medicine* **54**, 2054–2062. <https://doi.org/10.1017/S003329172400014X>

Received: 27 June 2023

Revised: 11 December 2023

Accepted: 10 January 2024

First published online: 6 March 2024

**Keywords:**

brain morphology; inflammation; Mendelian randomization; schizophrenia

**Corresponding author:**

Qiang Wang;

Email: [wangqiang130@scu.edu.cn](mailto:wangqiang130@scu.edu.cn);

Tao Li;

Email: [litaozjus@zju.edu.cn](mailto:litaozjus@zju.edu.cn)

# Temporal changes in brain morphology related to inflammation and schizophrenia: an omnigenic Mendelian randomization study

Yunjia Liu<sup>1,2,\*</sup>, Hongyan Ren<sup>1,2,\*</sup>, Yamin Zhang<sup>3,4,5</sup>, Wei Deng<sup>3,4,5</sup>, Xiaohong Ma<sup>1</sup>, Liansheng Zhao<sup>1</sup>, Xiaojing Li<sup>3,4,5</sup>, Pak Sham<sup>6</sup>, Qiang Wang<sup>1</sup>  and Tao Li<sup>2,3,4,5,7</sup> 

<sup>1</sup>Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; <sup>2</sup>Nanhu Brain-computer Interface Institute, Hangzhou 311100, China; <sup>3</sup>Affiliated Mental Health Center & Hangzhou Seventh People's Hospital and School of Brain Science and Brain Medicine, Zhejiang University School of Medicine, Hangzhou, 310058, China; <sup>4</sup>Lingang Laboratory, Shanghai 200031, China; <sup>5</sup>Liangzhu Laboratory, MOE Frontier Science Center for Brain Science and Brain-machine Integration, State Key Laboratory of Brain-machine Intelligence, Zhejiang University, 1369 West Wenyi Road, Hangzhou 311121, China; <sup>6</sup>State Key Laboratory of Brain and Cognitive Sciences, Centre for Genomic Sciences, and Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China and <sup>7</sup>NHC and CAMS Key Laboratory of Medical Neurobiology, Zhejiang University, Hangzhou 310058, China

**Abstract**

**Background.** Over the past several decades, more research focuses have been made on the inflammation/immune hypothesis of schizophrenia. Building upon synaptic plasticity hypothesis, inflammation may contribute the underlying pathophysiology of schizophrenia. Yet, pinpointing the specific inflammatory agents responsible for schizophrenia remains a complex challenge, mainly due to medication and metabolic status. Multiple lines of evidence point to a wide-spread genetic association across genome underlying the phenotypic variations of schizophrenia.

**Method.** We collected the latest genome-wide association analysis (GWAS) summary data of schizophrenia, cytokines, and longitudinal change of brain. We utilized the omnigenic model which takes into account all genomic SNPs included in the GWAS of trait, instead of traditional Mendelian randomization (MR) methods. We conducted two round MR to investigate the inflammatory triggers of schizophrenia and the resulting longitudinal changes in the brain.

**Results.** We identified seven inflammation markers linked to schizophrenia onset, which all passed the Bonferroni correction for multiple comparisons (bNGF, GROA(CXCL1), IL-8, M-CSF, MCP-3 (CCL7), TNF- $\beta$ , CRP). Moreover, CRP were found to significantly influence the linear rate of brain morphology changes, predominantly in the white matter of the cerebrum and cerebellum.

**Conclusion.** With an omnigenic approach, our study sheds light on the immune pathology of schizophrenia. Although these findings need confirmation from future studies employing different methodologies, our work provides substantial evidence that pervasive, low-level neuroinflammation may play a pivotal role in schizophrenia, potentially leading to notable longitudinal changes in brain morphology.

**Introduction**

Schizophrenia (SCZ) is a complex disorder characterized by a genetic architecture that includes polygenicity and pleiotropy (Ripke *et al.*, 2013; Schizophrenia Working Group of the Psychiatric Genomics, 2014). Recent advances in genotyping and sequencing technology, alongside multinational collaborations for sample collections as epitomized by Psychiatric Genomic Consortium (PGC), have facilitated genome-wide scans for risk variants of SCZ in a well-powered sample. These developments have provided fresh insights into the architecture and pathogenesis of SCZ. However, mapping the complete genetic architecture underlying the complex disease like SCZ and translating the existing GWAS results remains elusive, the methods such as polygenic risk score only involves variants passing certain significance thresholds and can only explain a small proportion of phenotypic variation, a problem dubbed 'the missing heritability' (Zuk, Hechter, Sunyaev, & Lander, 2012). In a groundbreaking study, Boyle *et al.*, proposed an omnigenic model, suggesting that in disease-relevant cell types, essentially all genes contribute to the condition (Boyle, Li, & Pritchard, 2017). Concurrently, three waves of genome-wide association studies (GWASs) by the PGC indicated a potentially critical role for inflammation/infection in the pathophysiological mechanism of SCZ, with the most associated genomic regions highlighting the MHC region on chromosome 6 (Pardiñas *et al.*, 2018; Schizophrenia Working Group of the Psychiatric Genomics, 2014; Trubetsky *et al.*, 2022).

© The Author(s), 2024. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Despite abundant evidence supporting inflammation's role in SCZ (Khandaker et al., 2015; Sellgren et al., 2021), determining specific inflammatory markers indicative of SCZ remains challenging. The most detectable and widespread inflammatory molecules in the peripheral blood system are cytokines and chemokines, which maintain immune cell homeostasis and coordinate immune responses (Ramesh, MacLean, & Philipp, 2013). Recent conceptual shifts have reframed the relationship between the brain and the immune system. It is now accepted that the brain is not immune-privileged and that brain cells like neurons and microglia release cytokines essential for both normal function and disease states (Kwon, 2022). In the context of schizophrenia, researchers have found evidence of cytokines such as C-reactive protein (CRP), IL-1 $\beta$ , IL-6, IL-12, interferon- $\gamma$ , and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) being associated with endophenotypes and varying disease status of schizophrenia (Lesh et al., 2018; Lin et al., 2021).

While promising, these findings are not always consistent due to methodological heterogeneity and moderate study sample sizes. Other factors can also confound the investigation of cytokine levels in the peripheral blood in schizophrenia, including antipsychotics, metabolites, comorbid inflammatory conditions, and age (Decker, Gotta, Wellmann, & Ritz, 2017; Himmerich, Patsalos, Lichtblau, Ibrahim, & Dalton, 2019). Furthermore, ongoing debates exist regarding the causal inference of regression analysis, the most commonly used statistical method in association studies. Linear regression implies causality only if the covariates are from a controlled experiment and the experiment isolates the hypothesized causal factor well (Constantine, 2012). Unfortunately, most association studies with cytokine levels as covariates were conducted in a non-experimental controlled manner. Mendelian randomization (MR) provides a useful tool for detecting causal relationships between phenotype pairs, generating a more robust causal estimate due to the immutability of genotypes as instrument variables (IVs, randomization at birth) (Sanderson et al., 2022). Two-sample MR, which utilizes publicly accessible summary-level data from GWAS, has gained popularity in recent years due to free access to a vast resource of GWAS results of various phenotypes or traits (Hemani et al., 2018). Unlike one-sample MR, two-sample MR does not require the effect of the IV-exposure association and the IV-outcome factor association to be collected from the same participant sample, potentially avoiding confounding factors such as the 'winner's curse' (Zou et al., 2022).

A previous two-sample MR study by Hartwig et al., suggests a negative (protective) effect of CRP and a risk-increasing (positive) effect of sIL-6R (potentially mediated at least in part by CRP) on the lifetime risk of schizophrenia. (Hartwig, Borges, Horta, Bowden, & Davey Smith, 2017). However, their study had several limitations. Following the conventional hypothesis of MR, the study by Hartwig et al., chose the SNPs, the association of which reached the genome-wide significance, to be IVs in the causal inference of MR. However, many previous studies showed that even the SNPs with large effect-sizes could only explain a small proportion of phenotypic variation, thus under-estimating the MR estimate (Davies, Holmes, & Davey Smith, 2018). The current study, taking into account the genetic architecture of complex diseases such as SCZ and assuming an omnigenic model in which essentially all genes contribute to the phenotypic variation of complex traits, includes all genome-wide SNPs as IVs to answer two questions: (1) What does the pathogenesis of schizophrenia trigger the immune response in terms of inflammatory molecules, including cytokines, chemokines and CRP (SCZ-triggering inflammatory markers)? The ENIGMA (Enhancing NeuroImaging Genetics

through Meta-Analysis) consortium recently highlighted genetic variants associated with longitudinal changes in brain structure (Brouwer et al., 2022), and various studies have identified systemic inflammation as a predictor of brain aging (Corlier et al., 2018), which leads to our second question: (2) What is the impact of SCZ-triggering inflammatory markers on longitudinal brain changes? (Fig. 1).

## Materials and methods

### Data source

The MR analysis of SCZ and inflammation in our study utilized, as the exposure, the summary statistics of the schizophrenia GWAS conducted by Trubetskoy et al., which comprised 76 755 cases and 243 649 controls of European ancestry (Trubetskoy et al., 2022). For the inflammation outcomes, we used the summary statistics of GWAS of 41 cytokines/chemokines in the peripheral blood of 8293 healthy volunteers of European ancestry (Kalaoja et al., 2021) (online Supplementary Table S2). For CRP, we selected the summary statistics of the latest CRP GWAS conducted on 427 367 participants of European descent (Said et al., 2022). No significant sample overlapping was observed within the three datasets (SCZ, cytokines/chemokines, and CRP).


The SCZ-triggering inflammatory markers identified in the first analysis were taken to a second MR analysis of inflammation and longitudinal morphology change in fifteen brain phenotypes, including the amygdala, caudate, cerebellum gray matter, cerebellum white matter, cerebral white matter, cortical gray matter, hippocampus, lateral ventricles, cortical mean thickness, nucleus accumbens, pallidum, putamen, surface area, thalamus, and total brain volume. For the outcome measure, we chose the GWAS summary statistics of longitudinal changes (following-up period no less than six months) in brain structure conducted by the ENIGMA consortium in a sample of 15 640 individuals of European descent (Brouwer et al., 2022). There was no known sample overlapping between these two datasets. The details of all the summary data included in the analysis were listed in online Supplementary Table S1.

### Two-sample MR analysis

Given easy access to GWAS results, numerous methods have been developed for two-sample MR analysis. Yet, most of these methods require (1) using SNPs with significant association at the genome-wide level as IVs and (2) the selected IVs are independent of each other, i.e. in linkage equilibrium (LD). However, schizophrenia, like many other complex diseases/traits, is a polygenic and even omnigenic disease. Furthermore, the independent IVs in a less perfect LD with the true causal ones could lead to power loss. To tackle these issues and increase the power of causal inference, Lu et al., based on the concept of the omnigenic model, developed a new analysis framework for two-sample MR studies called omnigenic Mendelian randomization (OMR) (Wang, Gao, Fan, Xue, & Zhou, 2021). The OMR relaxes the relevance and independence assumptions by including all genome-wide SNPs as IVs and explicitly controlling for the potential horizontal pleiotropy by including an additional term,  $G_y\gamma$ , in the equation below.

$$x = 1_{nx}\mu_x + G_x\beta + \varepsilon_x \quad (1)$$

$$y = 1_{ny}\mu_y + G_y\beta\alpha + G_y\gamma + \varepsilon_y \quad (2)$$



**Figure 1.** Schematic illustration of the analysis framework in our study. Two black rectangles demonstrate the two sequential phases: the initial ‘Discovery Phase’ (the upper one) involves the utilization of omnigenetic schizophrenia (SCZ) genotypes (IVs) to identify the inflammation markers with a potential causal relationship to SCZ. Moving to the second ‘Replication Phase’ (the lower one), the same omnigenetic IVs associated with SCZ-triggering inflammation markers were employed to identify the brain regions exhibiting causal linear morphological changes. Concurrently, for each MR analysis, we calculated the degree of horizontal pleiotropy effect on outcome measures. The lower panel portrays the methods employed to replicate our main results. The left side gives an overview of the MRMix algorithm, while the right exhibits a Manhattan plot detailing multiple psychotic experiences used in the replication phase.

In the equation above,  $\mathbf{1}$  represents a vector of 1’s with the corresponding dimensionality shown in the subscript,  $\mu_x$  is the intercept for the exposure model;  $\mu_y$  is the intercept for the outcome model;  $n_x$  and  $n_y$  are the sample size of GWASs for exposure measure and outcome measure, respectively;  $\beta$  is the genotype effect on the exposure variable;  $\gamma$  is the horizontal pleiotropy effect of SNPs on the outcome variable;  $\alpha$  is a scalar that represents the causal effect of the exposure variable on the outcome variable;  $x$  and  $y$  are residual error vectors of size  $n_x$  and  $n_y$ , respectively. The OMR constructs a log composite likelihood as a weighted combination of the log marginal likelihood. Both simulation and real dataset analysis showed that, compared with other methods, OMR showed superiority in controlling type I error and horizontal pleiotropy effect across different genetic architectures.

We used the R package ‘OMR’ to perform the omnigenic MR analyses. To harmonize the data, we implemented the quality control and merged two data sets with reference panel from the 1000 Genomes Project Phase3. Each OMR analysis output includes two primary parameters: the causal effect ( $\alpha$ ) and the proportion of SNP horizontal pleiotropy effect in the outcome variable ( $\gamma$ ). Figure 1 displays the analysis framework of this study. We defined SCZ-triggering inflammatory markers as ones with a significant  $p$  value surviving the Bonferroni multiple comparison correction ( $0.05/42 = 0.00119$ ). These markers were then chosen as the exposure in the second round of MR analysis

of inflammation  $\Rightarrow$  longitudinal morphology change of the brain, with the  $p$  value being corrected for Bonferroni multiple comparisons ( $0.05/(15 \times 7) = 0.000477$ ).

**Replication analysis**

To evaluate the robustness of our main results, we carried out a two-layered replication analysis. For the first layer, we chose a different MR method, ‘MRMix’, a multiple-variant approach (Qi & Chatterjee, 2019), to re-run the analysis on the inflammation markers showing a significant causal link with longitudinal brain changes in the previous step. For the second layer, we selected a different dataset, GWAS of multiple psychotic experiences, to replicate the primary results of SCZ  $\Rightarrow$  inflammation (Legge *et al.*, 2019).


**Results**

**Seven inflammation markers showing a significant change in response to schizophrenia**

The results of SCZ  $\Rightarrow$  inflammation analyses are summarized in Table 1 and Fig. 2. Omnigenic IVs of SCZ led to the change of seven inflammation markers in the peripheral blood. The most significant was CRP, with a causal estimate of  $-0.035$  [ $-0.04$  to

**Table 1.** Causal estimates of six cytokines/chemokines and CRP in MR analysis of SCZ  $\Rightarrow$  inflammation using OMR

Inflammation markers	$\alpha$		$\beta$	$\gamma$	$Z$	$p$
	Causal effects	95% CI				
bNGF	-0.101	(-0.14 to -0.07)	0.005	0.001	-5.667	$1.45 \times 10^{-8}$
GROA (CXCL1)	-0.068	(-0.10 to -0.03)	0.005	0	-3.857	$1.15 \times 10^{-4}$
IL-8	0.086	(0.05 to 0.12)	0.005	0.002	5.087	$3.64 \times 10^{-7}$
M-CSF	-0.078	(-0.12 to -0.03)	0.005	0	-3.311	$9.30 \times 10^{-4}$
MCP-3 (CCL7)	-0.129	(-0.18 to -0.08)	0.005	0.004	-4.840	$1.3 \times 10^{-6}$
TNF- $\beta$	-0.086	(-0.13 to -0.04)	0.005	0	-3.566	$3.63 \times 10^{-4}$
CRP	-0.035	(-0.04 to -0.03)	0.005	0.002	-11.869	$1.71 \times 10^{-32}$

**Figure 2.** Causal estimates and corresponding 95% confidence intervals of seven inflammation markers that generated significant  $p$  values in the MR analysis of schizophrenia  $\Rightarrow$  inflammation.

The red line denotes no causal effect between schizophrenia and inflammation markers. The vertical bars above the red line represent inflammation markers whose level increases by one standard unit for each additional standard deviation (s.d.) in the risk of schizophrenia. Conversely, the bars below the red line signify estimates of inflammation markers whose level decrease for each s.d. increase in the risk of schizophrenia.

-0.03] ( $\alpha$ , causal effects with 95% CI) in response to schizophrenia ( $p$  value =  $1.71 \times 10^{-32}$ ), and approximately 0.1% of SNPs involved indicated horizontal pleiotropy. The second most significant inflammation marker, bNGF (basic nerve growth factor),

decreased by 0.10 in the peripheral blood as the quantitative risk of SCZ increased with each standard deviation (s.d.) unit (bNGF:  $\alpha$  = -0.101 [-0.136 to -0.066],  $p$  value =  $1.45 \times 10^{-8}$ ). We observed systematic immunological deficits in the

inflammatory response to SCZ, with only IL-8 exhibiting an elevated level in response to schizophrenia (IL-8:  $\alpha = 0.086$  [0.053–0.119],  $p$  value =  $3.64 \times 10^{-7}$ ). Interestingly, GROA (CXCL1), which could bind to the same receptor as IL-8 and CXCR2, was also significantly involved, with its mean value decreasing by 0.068 as the risk for SCZ increased each s.d. unit, implicating the role of the IL-8 pathway in the inflammatory mechanism of SCZ (GROA:  $\alpha = -0.068$  [–0.103 to –0.034],  $p$  value =  $1.15 \times 10^{-4}$ ).

For horizontal pleiotropy, most causal estimates of identified markers, except those of GROA (CXCL1) and M-CSF, indicated varying yet relatively modest degrees of horizontal pleiotropy, signaling a potentially exclusive pathway linking SCZ to these markers.

### CRP as the SCZ-triggering inflammation marker conferring impact on the longitudinal morphology change of different brain regions

In the second round of MR analysis of inflammation  $\Rightarrow$  the longitudinal brain changes, three out of seven SCZ-triggering inflammation markers, GROA (CXCL1), IL-8 and CRP, caused the significant longitudinal change in the different brain regions. Specifically, CRP led to the most significant and wide-ranging linear change in the brain morphology: one standard unit increase of CRP in the peripheral blood could lead to an increase in the mean change rate of the cerebral white matter by 0.064 [0.396–0.089] ( $p$  value =  $3.588 \times 10^{-7}$ ), a reduction in the change rate of pallidum by 0.053 [0.034–0.072] ( $p$  value =  $4.02 \times 10^{-8}$ ), and an increase in change rate by 0.041 [0.020–0.061] in the surface area ( $p$  value =  $8.67 \times 10^{-5}$ ). CRP also caused a decrease in the mean linear change rate by 0.033 [0.014–0.052] in the white matter of cerebellum, with a  $p$  value falling short of multiple comparison corrections ( $p$  value =  $6.7 \times 10^{-4}$ ). Additionally, at a nominally significant level, we also detected some probably causal relationship. A decrease in linear change rate of lateral ventricles (LCs) mean value was found associated with an increased rate of 0.204 [0.042–0.366] of GROA ( $p$  value = 0.01). IL-8 was casually associated with the linear change rate of cerebral white matter ( $\alpha = -0.253$  [–0.43 to –0.07],  $p$  value = 0.0064) and amygdala ( $\alpha = -0.528$  [–0.961 to –0.096],  $p$  value = 0.017). The findings are summarized in the pathway diagram in Fig. 3.

Replication using MRMix validated the significant causal relationship of schizophrenia to the three inflammation markers mentioned above. As displayed in Fig. 4, the direction of the causal effect arising from MRMix was consistent with those from OMR for all markers except for GROA (CXCL1), which generated a positive estimate of 0.01 instead of a negative causal effect. Using the GWAS summary statistics of multiple psychotic experiences from the UK biobank, we identified the causal relationship between multiple psychotic experiences and CRP as nominally significant ( $\alpha = -0.01$ ,  $p$  value = 0.045).

## Discussion

In an innovative approach, our study employed an omnigenic model to elucidate the immunological aspects of schizophrenia and their effect on longitudinal changes in brain morphology. We found several inflammatory markers associated to schizophrenia, indicating a systematic immunological imbalance in schizophrenia. Notably, we discovered that three SCZ-triggering markers, CRP, GROA (CXCL1), and IL-8, significantly influence the linear change rate of brain structures, especially the white


matter. The subsequent analysis using MRMix confirmed our primary findings for all three markers, and we also discerned the causal implication of CRP through the ‘multiple psychotic experiences’ results.

The key findings of our study include the causal relationship between schizophrenia and CRP and a directed relationship between CRP and the linear change rate in multiple brain regions. The former finding is partially consistent with the study by Hartwig et al. (Hartwig et al., 2017). While Hartwig et al., suggests a negative (protective) effect of CRP on the lifetime risk of schizophrenia, our study implies that as the quantitative risk of SCZ increased by one standard unit, the mean value of CRP decreased by 0.035. Notably, as the quantitative risk of SCZ increased by one standard unit, the mean value of CRP decreased by 0.035. CRP, an acute-phase protein predominantly secreted by hepatocytes, can also be produced by neurons in response to infection (Yasojima, Schwab, McGeer, & McGeer, 2000). Presenting either as a pentameric form (pCRP) or as individual monomers at sites of inflammation (CRP), our findings echo prior research, suggesting a low-grade yet continuous anomaly in CRP is fundamental to the pathogenesis of SCZ, such as intrauterine influences and stress, lead to immunological deficits. These deficits are exemplified by the reduction in CRP level observed in our study.

These immunological deficits, combined with later-life environmental factors, could precipitate the onset of schizophrenic symptoms. Moreover, our subsequent MR analysis indicated that CRP significantly contributes to deviant longitudinal morphological changes in various brain regions, especially white matter volume (WMV). Prior research has proposed that inflammation could cause abnormalities in white matter, including lesions (Wu, 2012) and WMV changes (Raz, Yang, Dahle, & Land, 2012). Our findings estimated an increase in cerebral white matter mean value and a decrease in cerebellar WMV mean value as CRP increases. As per a foundational study by Bethlehem et al., WMV increased rapidly from mid-gestation to early childhood, peaking in young adulthood, which coincides with the typical onset age of schizophrenia (Bethlehem et al., 2022). Our results suggest that longitudinal changes in CRP levels caused by SCZ lead to divergent growth trajectories of WMV in cerebral and cerebellar areas. Our study also established the causal link from CRP to the pallidum’s GMV longitudinal changes, which play a significant role in various mental functions (Klaassen, Heiniger, Vaca Sánchez, Harvey, & Rainer, 2021; Takeuchi et al., 2017). Considering the omnigenic model, maybe we could cautiously speculate that the local region is influenced by the core genes and the whole cerebral white matter by the peripheral genes.

Interestingly, Weiqiu et al., identified a notable shared genetic architecture between schizophrenia and subcortical volumes, precisely 54% for schizophrenia. Consistent with our hypothesis, they also found that shared genetic loci peaked at the prenatal age, suggesting that the pathogenesis of schizophrenia, especially immunological aspects, could start around the perinatal period, potentially triggered or exacerbated by intrauterine infection or inflammation involving CRP (Cheng et al., 2022). Moreover, we could further infer that synaptic plasticity play a vital role in the underlying pathophysiology. As in the previous PGC3 SCZ GWAS, risk genes are expressed in the both excitatory and inhibitory of neurons, which is also associated with inflammation (de Bartolomeis et al., 2022).

Our study also identified another SCZ-triggering inflammatory marker, GROA (CXCL1), which could lead to a decreased linear change rate in the lateral ventricle. GROA, structurally




**Figure 3.** The schematic diagrams illustrating the causal effect of significant SCZ-triggering inflammation markers, CRP, on linear morphology change within different brain regions. Each diagram contains the causal effect estimates. In addition to these causal estimates, we also calculated the impact of horizontal pleiotropy, generated by the omnigenic IVs, on the morphological changes within the brain. (IVs, instrumental variables; CRP, C-reactive Protein; WM, white matter).

similar to interleukin-8 (IL-8), has potent neutrophil-stimulating activity (Geiser, Dewald, Ehrenguber, Clark-Lewis, & Baggiolini, 1993). Several studies have demonstrated its significant differences in both gene expression and DNA methylation between patients with SCZ and healthy controls, as well as among different subtypes of schizophrenia (Zhou et al., 2018). In the CNS, CXCL1 primarily binds to CXCR2 and promotes the proliferation of neuronal stem cells (NSCs) in both vitro and vivo, especially in the subventricular zone of the lateral ventricle (Shang et al., 2019). Our analysis generated a negative causal estimate, hinting at the possible suppression effect of SCZ on the GROA (CXCL1) level and subsequently on the proliferation and migration of NSCs.

We also found IL-8, another SCZ-triggering inflammation marker, to influence the linear change rate of brain morphology. IL-8, a crucial mediator of the immune response, is typically synthesized by glial cells and astrocytes in the CNS

(Atta-ur-Rahman, Harvey, & Siddiqui, 1999; Ehrlich et al., 1998). Our analysis of SCZ and inflammation indicated a positive causal effect of schizophrenia on IL-8, implying that schizophrenia could lead to increased IL-8 level, a finding in line with previous studies (Boerrigter et al., 2017; Brown et al., 2004). Furthermore, we discovered that IL-8 results in a decreased change rate of cerebral white matter. Potential roles IL-8 could play in neuroinflammation include facilitating the synthesis of pro-apoptotic protein, inducing the gene expression of pro-inflammatory proteases with neurotoxic properties, and recruitment of immune cells to the inflammation sites (Ramesh et al., 2013). Of note, both IL-8 and GROA (CXCL1) belong to the same CXC group, which could bind to CXCR2 with high affinity (Waugh & Wilson, 2008). Giovannelli et al., using the patch clamp technique and laser confocal microscopy, demonstrated that IL-8 and GROA could modulate the activity of Purkinje neurons in the mouse cerebellum (Giovannelli et al.,



**Figure 4.** Grid search results for the causal effects ( $\theta$ ) of schizophrenia on CRP, GROA (CXCL1) and IL-8. We aimed to discern the causal effect ( $\theta$ ) of schizophrenia on CRP (a), GROA (b), and IL-8 (c). The vertical red dashed line in each graph indicates the causal estimates corresponding to the probability mass's peak.

1998). Besides, our study indicated that IL-8 and GROA could cause significant longitudinal changes in cerebral white matter and lateral ventricle. A neuroimaging study found a strong association between white matter diffusivity and ventricle volume in patients with Alzheimer's disease (AD) (Coutu, Goldblatt, Rosas, Salat, & Alzheimer's Disease Neuroimaging, 2016), which strongly suggests that further investigations are warranted to unravel the cellular mechanism of the IL-8 pathway-mediated effect on cerebral white matter in the schizophrenia.

Additionally, our study identified that while the peripheral level of bNGF, M-CSF, MCP-3 and TNF- $\beta$  could be altered by schizophrenia, they were not found to be causally associated with the linear change rate of brain morphology. bNGF is a neurotrophic factor that regulates the functions of differentiated neurons (Aloe, Rocco, Balzamino, & Micera, 2015). Prior studies found its dysfunction in schizophrenia, especially its role in the structural deviation of brain, including areas highly involved in crucial cognitive functions such as the prefrontal and temporal

cortex. Our findings of decreased bNFG level suggest a deficit neurodevelopmental process preceded or precipitated by inflammation or infection. M-CSF, macrophage colony-stimulating factor, is a widely expressed cytokine that stimulates progenitor cells from bone marrow and subsequent development, proliferation and maintenance of mononuclear phagocytes such as dendritic cells and microglia (Hume & MacDonald, 2012). M-CSF, along with anti-inflammatory factors such as TNF- $\beta$ , can polarize microglia towards anti-inflammatory (M2) directions (Pons & Rivest, 2018). Both M-CSF and TNF- $\beta$  showed lower levels in response to the pathogenesis of schizophrenia, hinting at a potential early-onset dysfunction in restricting neuroinflammation.

MCP-3 (CCL7), the monocyte chemoattractant protein 3, belongs to the MCP subgroup of CXC chemokines and is a potent chemoattractant for various leukocytes, including dendritic cells (DCs) (Liu, Cai, Liu, Wu, & Xiong, 2018). Cathomas et al., found a significantly lowered level of CCL7 in patients with SCZ, consistent with our estimates (Cathomas et al., 2021). We did not find any causal relationship between these five cytokines and the linear change in brain morphology, and it is theoretically possible that they might exert their effects through other pathophysiological processes, possibly in a time-specific manner.

While our study, to the best of our knowledge, is the first study to utilize an omnigenic conceptual framework to elucidate the inflammatory implications of schizophrenia and the influence of these inflammatory factors on the temporal change in brain morphology, we are fully aware of its limitations. Despite efforts to validate the robustness of our findings by replicating initial results with a different methodology and dataset, several constraints remain. First, we could not eliminate all potential confounders in our MR analyses, thereby possibly violating the exclusion restriction assumption. Given the inherent polygenic or omnigenic nature of complex diseases and traits, the human genome has widespread pleiotropy. Consequently, it is currently impractical to identify and account for all potential confounding factors. It should also be noted that most variants are common but with less disease specificity in the GWAS summary data. Secondly, our study only carried out a unidirectional MR analysis. We refrained from exploring the causality of a cytokine to schizophrenia out of concern that the instrumental variables (IVs) for cytokines would be severely biased towards under-powering due to the modest sample size of cytokine GWAS.

## Conclusion

In conclusion, leveraging an omnigenic conceptual framework, we explored the inflammatory mediators of schizophrenia and their impact on the temporal longitudinal change in brain morphology. Our results spotlight systematic, albeit low-grade, immune alterations set in motion by the onset of schizophrenia. Importantly, these immune changes can, over time, exacerbate the risk of schizophrenia by disrupting the structural integrity of both cortical and subcortical regions.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S003329172400014X>

**Acknowledgements.** This work was partly supported by National Natural Science Foundation of China (grant number 81920108018 to T.L. and P.S.), the Key R & D Program of Zhejiang (2022C03096 to T.L.), Project for Hangzhou Medical Disciplines of Excellence & Key Project for Hangzhou Medical Disciplines (grant number 202004A11 to T.L.), grants from Nanhu Brain-computer Interface Institute (T.L.), National Natural Science

Foundation of China (grant number 82171499 to Q.W.) Chinese National Programs for Brain Science and Brain-like Intelligence Technology-China Depression Cohort Study (2021ZD0200700 to Q.W.), and Science and Technology Project of Sichuan Province (2023YFS0030 to Q.W.).

**Competing interests.** None.

## References

- Aloe, L., Rocco, M. L., Balzamino, B. O., & Micera, A. (2015). Nerve growth factor: A focus on neuroscience and therapy. *Current Neuropharmacology*, 13(3), 294–303.
- Atta-ur-Rahman, N., Harvey, K., & Siddiqui, R. A. (1999). Interleukin-8: An autocrine inflammatory mediator. *Current Pharmaceutical Design*, 5(4), 241–253.
- Bethlehem, R. A. I., Seidlitz, J., White, S. R., Vogel, J. W., Anderson, K. M., Adamson, C., ... Alexander-Bloch, A. F. (2022). Brain charts for the human lifespan. *Nature*, 604(7906), 525–533.
- Boerrigter, D., Weickert, T. W., Lenroot, R., O'Donnell, M., Galletly, C., Liu, D., ... Weickert, C. S. (2017). Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. *Journal of Neuroinflammation*, 14(1), 188.
- Boyle, E. A., Li, Y. L., & Pritchard, J. K. (2017). An expanded view of complex traits: From polygenic to omnigenic. *Cell*, 169(7), 1177–1186.
- Brouwer, R. M., Klein, M., Grasby, K. L., Schnack, H. G., Jahanshad, N., Teuuw, J., ... Hulshoff Pol, H. E. (2022). Genetic variants associated with longitudinal changes in brain structure across the lifespan. *Nature Neuroscience*, 25(4), 421–432.
- Brown, A. S., Hooton, J., Schaefer, C. A., Zhang, H., Petkova, E., Babulas, V., ... Susser, E. S. (2004). Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. *The American Journal of Psychiatry*, 161(5), 889–895.
- Cathomas, F., Klaus, F., Guetter, K., Chung, H.-K., Raja Beharelle, A., Spiller, T. R., ... Kaiser, S. (2021). Increased random exploration in schizophrenia is associated with inflammation. *NPJ Schizophrenia*, 7(1), 6.
- Cheng, W., van der Meer, D., Parker, N., Hindley, G., O'Connell, K. S., Wang, Y., ... Andreassen, O. A. (2022). Shared genetic architecture between schizophrenia and subcortical brain volumes implicates early neurodevelopmental processes and brain development in childhood. *Molecular Psychiatry*, 27(12), 5167–5176.
- Constantine, N. A. (2012). Regression analysis and causal inference: Cause for concern? *Perspectives on Sexual and Reproductive Health*, 44(2), 134–137.
- Corlier, F., Hafzalla, G., Faskowitz, J., Kuller, L. H., Becker, J. T., Lopez, O. L., ... Braskie, M. N. (2018). Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk. *NeuroImage*, 172, 118–129.
- Coutu, J.-P., Goldblatt, A., Rosas, H. D., Salat, D. H., & Alzheimer's Disease Neuroimaging, I. (2016). White matter changes are associated with ventricular expansion in aging, mild cognitive impairment, and Alzheimer's disease. *Journal of Alzheimer's disease: JAD*, 49(2), 329–342.
- Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018). Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. *BMJ (Clinical research ed.)*, 362, k601.
- de Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccirelli, M. (2022). Linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes: Translational relevance for schizophrenia and antipsychotic treatment: A systematic review. *Molecular Neurobiology*, 59(10), 6460–6501. doi: 10.1007/s12035-022-02976-3
- Decker, M.-L., Gotta, V., Wellmann, S., & Ritz, N. (2017). Cytokine profiling in healthy children shows association of age with cytokine concentrations. *Scientific Reports*, 7(1), 17842.
- Ehrlich, L. C., Hu, S., Sheng, W. S., Sutton, R. L., Rockswold, G. L., Peterson, P. K., & Chao, C. C. (1998). Cytokine regulation of human microglial cell IL-8 production. *Journal of Immunology (Baltimore, Md.: 1950)*, 160(4), 1944–1948.
- Geiser, T., Dewald, B., Ehrenguber, M. U., Clark-Lewis, I., & Baggiolini, M. (1993). The interleukin-8-related chemotactic cytokines GRO alpha, GRO

- beta, and GRO gamma activate human neutrophil and basophil leukocytes. *The Journal of Biological Chemistry*, 268(21), 15419–15424.
- Giovannelli, A., Limatola, C., Ragozzino, D., Mileo, A. M., Ruggieri, A., Ciotti, M. T., ... Eusebi, F. (1998). CXC Chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. *Journal of Neuroimmunology*, 92(1–2), 122–132.
- Hartwig, F. P., Borges, M. C., Horta, B. L., Bowden, J., & Davey Smith, G. (2017). Inflammatory biomarkers and risk of schizophrenia: A 2-sample Mendelian randomization study. *JAMA Psychiatry*, 74(12), 1226–1233.
- Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., ... Haycock, P. C. (2018). The MR-base platform supports systematic causal inference across the human phenome. *eLife*, 7, e34408.
- Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019). Cytokine research in depression: Principles, challenges, and open questions. *Frontiers in Psychiatry*, 10, 30.
- Hume, D. A., & MacDonald, K. P. A. (2012). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. *Blood*, 119(8), 1810–1820.
- Kalaoja, M., Corbin, L. J., Tan, V. Y., Ahola-Olli, A. V., Havulinna, A. S., Santalahti, K., ... Timpson, N. J. (2021). The role of inflammatory cytokines as intermediates in the pathway from increased adiposity to disease. *Obesity (Silver Spring, Md.)*, 29(2), 428–437.
- Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015). Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. *The Lancet. Psychiatry*, 2(3), 258–270.
- Klaassen, A.-L., Heiniger, A., Vaca Sánchez, P., Harvey, M. A., & Rainer, G. (2021). Ventral pallidum regulates the default mode network, controlling transitions between internally and externally guided behavior. *Proceedings of the National Academy of Sciences of the United States of America*, 118(36), e2103642118.
- Kwon, D. (2022). Guardians of the brain: How a special immune system protects our grey matter. *Nature*, 606(7912), 22–24, %\* 2022 Springer Nature Limited %U. <https://www.nature.com/articles/d41586-41022-01502-41588>
- Legge, S. E., Jones, H. J., Kendall, K. M., Pardiñas, A. F., Menzies, G., Bracher-Smith, M., ... Walters, J. T. R. (2019). Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. *JAMA Psychiatry*, 76(12), 1256–1265.
- Lesh, T. A., Careaga, M., Rose, D. R., McAllister, A. K., Van de Water, J., Carter, C. S., & Ashwood, P. (2018). Cytokine alterations in first-episode schizophrenia and bipolar disorder: Relationships to brain structure and symptoms. *Journal of Neuroinflammation*, 15(1), 165.
- Lin, C., Chen, K., Yu, J., Feng, W., Fu, W., Yang, F., ... Chen, D. (2021). Relationship between TNF- $\alpha$  levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. *BMC Psychiatry*, 21(1), 561.
- Liu, Y., Cai, Y., Liu, L., Wu, Y., & Xiong, X. (2018). Crucial biological functions of CCL7 in cancer. *PeerJ*, 6, e4928.
- Pardiñas, A. F., Holmans, P., Pocklington, A. J., Escott-Price, V., Ripke, S., Carrera, N., ... Walters, J. T. R. (2018). Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nature Genetics*, 50(3), 381–389.
- Pons, V., & Rivest, S. (2018). New therapeutic avenues of mCSF for brain diseases and injuries. *Frontiers in Cellular Neuroscience*, 12, 499.
- Qi, G., & Chatterjee, N. (2019). Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects. *Nature Communications*, 10(1), 1941.
- Ramesh, G., MacLean, A. G., & Philipp, M. T. (2013). Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. *Mediators of Inflammation*, 2013, 480739.
- Raz, N., Yang, Y., Dahle, C. L., & Land, S. (2012). Volume of white matter hyperintensities in healthy adults: Contribution of age, vascular risk factors, and inflammation-related genetic variants. *Biochimica Et Biophysica Acta*, 1822(3), 361–369.
- Ripke, S., O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., ... Sullivan, P. F. (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nature Genetics*, 45(10), 1150–1159.
- Said, S., Pazoki, R., Karhunen, V., Vösa, U., Ligthart, S., Bodinier, B., ... Dehghan, A. (2022). Genetic analysis of over half a million people characterises C-reactive protein loci. *Nature Communications*, 13(1), 2198.
- Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafo, M. R., ... Davey Smith, G. (2022). Mendelian randomization. *Nature Reviews Methods Primers*, 2(1), 6. doi: 10.1038/s43586-021-00092-5
- Schizophrenia Working Group of the Psychiatric Genomics, C (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature*, 511(7510), 421–427.
- Sellgren, C. M., Imbeault, S., Larsson, M. K., Oliveros, A., Nilsson, I. A. K., Codeluppi, S., ... Erhardt, S. (2021). GRK3 deficiency elicits brain immune activation and psychosis. *Molecular Psychiatry*, 26(11), 6820–6832.
- Shang, Y., Tian, L., Chen, T., Liu, X., Zhang, J., Liu, D., ... Shang, D. (2019). CXCL1 promotes the proliferation of neural stem cells by stimulating the generation of reactive oxygen species in APP/PS1 mice. *Biochemical and Biophysical Research Communications*, 515(1), 201–206.
- Takeuchi, H., Taki, Y., Nouchi, R., Yokoyama, R., Kotozaki, Y., Nakagawa, S., ... Kawashima, R. (2017). Global associations between regional gray matter volume and diverse complex cognitive functions: Evidence from a large sample study. *Scientific Reports*, 7(1), 10014.
- Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T. B., ... Schizophrenia Working Group of the Psychiatric Genomics, C. (2022). Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*, 604(7906), 502–508.
- Wang, L., Gao, B., Fan, Y., Xue, F., & Zhou, X. (2021). Mendelian randomization under the omnigenic architecture. *Briefings in Bioinformatics*, 22(6), bbab322.
- Waugh, D. J. J., & Wilson, C. (2008). The interleukin-8 pathway in cancer. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 14(21), 6735–6741.
- Wu, Y.-C. (2012). C-reactive protein and cerebral white matter lesions. *Clinical Neurology and Neurosurgery*, 114(1), 99–100.
- Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (2000). Human neurons generate C-reactive protein and amyloid P: Upregulation in Alzheimer's disease. *Brain Research*, 887(1), 80–89.
- Zhou, C., Chen, J., Tang, X., Feng, X., Yu, M., Sha, W., ... Zhang, X. (2018). DNA methylation and gene expression of the chemokine (C-X-C motif) ligand 1 in patients with deficit and non-deficit schizophrenia. *Psychiatry Research*, 268, 82–86.
- Zou, J., Zhou, J., Faller, S., Brown, R. P., Sankararaman, S. S., & Eskin, E. (2022). Accurate modeling of replication rates in genome-wide association studies by accounting for Winner's curse and study-specific heterogeneity. *G3 (Bethesda, Md.)*, 12(12), jkac261.
- Zuk, O., Hechter, E., Sunyaev, S. R., & Lander, E. S. (2012). The mystery of missing heritability: Genetic interactions create phantom heritability. *Proceedings of the National Academy of Sciences of the United States of America*, 109(4), 1193–1198. doi: 10.1073/pnas.1119675109